Humanin: the peptide your mitochondria write

Humanin is a very short peptide with an unusual origin: it is written not in the cell's nuclear DNA but in the mitochondrial genome. It was discovered in 2001 in a screen of brain tissue, where researchers looked for genes whose products kept neurons alive under conditions linked to Alzheimer's biology. The surviving signal traced back to a small open reading frame inside the mitochondrial 16S ribosomal RNA region, MT-RNR2, and the peptide it encodes was named humanin.

That origin made humanin the founding member of a class now called mitochondrial-derived peptides, or MDPs, which also includes MOTS-c and the SHLP series. The idea behind the class is retrograde signalling: mitochondria are usually cast as the cell's power plants, but these peptides suggest they also send out messenger molecules that influence the rest of the cell and, potentially, distant tissues. The broader claim, that mitochondria talk back to the cell through dedicated peptides, is a genuinely new way of thinking about an organelle usually described only in terms of energy output. Humanin is the most studied of the group.

A peptide written in mitochondrial DNA

The canonical humanin peptide is 24 amino acids long. Because the mitochondrial and nuclear codon systems differ slightly, a near-identical sequence can also be produced from nuclear copies of the mitochondrial region, and the literature reflects both routes. The practical point for a research audience is that humanin is short enough to make synthetically, which is why defined synthetic analogues, rather than extracted material, dominate the experimental record.

It is worth pausing on how strange the coding arrangement is. The mitochondrial genome is tiny, only about sixteen thousand base pairs, and it was long assumed to encode just thirteen proteins plus the RNAs needed to make them. Humanin and its relatives imply that short peptides are tucked inside the ribosomal RNA genes as well, a compact use of a small genome that researchers are still mapping.

What it appears to do in cell models

The recurring theme across the early work is cytoprotection. In cultured cells, humanin reduced apoptosis triggered by a range of insults, and mechanistic studies reported that it can bind and interfere with the pro-apoptotic protein Bax, keeping it from translocating to the mitochondria. A separate line of work described binding to insulin-like growth factor binding protein 3 (IGFBP3), tying humanin into growth-factor signalling.

Beyond raw survival signalling, humanin has been studied for effects on cellular metabolism and on stress responses in vascular and metabolic cell types. Reports describe interactions with insulin and glucose handling in model systems and protection of cells against oxidative and metabolic stress. As with the anti-apoptotic work, the picture is broad but the mechanisms are still being pieced together rather than nailed down.

On the receptor side, humanin has been reported to act through a trimeric cell-surface receptor built from CNTFR, WSX-1 and gp130, engaging the JAK/STAT pathway, and also through a formylpeptide-receptor-like route. The receptor biology is genuinely not settled, and different groups emphasise different complexes, which is worth keeping in mind when reading strong mechanistic claims.

The variants researchers use

Not all humanin is equal in the lab. A single-residue change, replacing serine 14 with glycine, produces an analogue known as S14G-humanin or HNG that is far more potent than the parent in many cell assays. The native peptide also carries a cysteine that lets it dimerise, and different preparations vary in how much of that dimer they contain. Because these variants behave differently, careful papers state exactly which form they used rather than writing humanin as if it were one fixed reagent.

Honest limitations

Almost all of the evidence is from cell culture and rodent models, and the jump from those systems to intact biology is large. The receptor story is contested. Reported potency depends heavily on which analogue and which assay were used, so cross-study comparisons are hazardous. Levels of the peptide reported in circulation vary widely between studies and assays, partly because measuring such a short peptide reliably is itself hard. And as a small peptide, humanin faces the usual questions of stability once in solution. None of this makes the biology uninteresting; it just means the honest reading is early-stage and mechanistic rather than settled.

For laboratory research use only. Not for human or veterinary use.

Common questions

Where does humanin come from in the genome?

From a short open reading frame inside the MT-RNR2 gene, the mitochondrial 16S ribosomal RNA region. That is unusual, because most peptides are encoded in nuclear DNA. Near-identical sequences can also arise from nuclear copies of mitochondrial segments, so both origins appear in the literature.

What is the difference between humanin and HNG?

HNG, also written S14G-humanin, is humanin with serine at position 14 swapped for glycine. That single change makes it much more potent than the native peptide in many in-vitro assays, which is why a lot of the published mechanistic work uses HNG rather than plain humanin.

Is humanin related to MOTS-c?

Yes, in the sense that both are mitochondrial-derived peptides encoded within mitochondrial ribosomal RNA regions. They are different molecules with different sequences and different reported targets, but they belong to the same conceptual family of small peptides that appear to carry signals outward from the mitochondria.

References

1. Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of Alzheimer's disease genes and Abeta. PNAS, 2001.
2. Guo B, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature, 2003.
3. Lee C, Yen K, Cohen P. Humanin: a harbinger of mitochondrial-derived peptides? Trends in Endocrinology and Metabolism, 2013.